You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
內地第九批國家組織藥品集中採購開標 涉42種藥品
內媒報道,內地第九批國家組織藥品集中採購今日(6日)早上在上海開標,是次集採涉及42種藥品,覆蓋高血壓、糖尿病及抗腫瘤等11個治療大類,其中約50%是注射劑型,包括阿托品注射劑、烏拉地爾注射劑型等。 據報,製藥公司已於今早8時陸續到場競交競標標書,接下來將進行公開現場開標,擬中選情況,隨後公布。 是次集採有一個顯著變化,藥品採購周期為4年,是國家組織藥品集採以來藥品採購周期最長的一次,有利於企業根據全國使用量等情況,制定長期發展策略,避免出現產能擴張後帶來的產能過剩等市場問題。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account